Pacific Biosciences of California (PACB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pacific Biosciences of California (PACB) has a cash flow conversion efficiency ratio of -18.889x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-44.69 Million) by net assets ($2.37 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Pacific Biosciences of California's balance sheet to measure how much of total assets are equity-financed.
Pacific Biosciences of California - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Pacific Biosciences of California's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Pacific Biosciences of California (PACB) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Pacific Biosciences of California Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pacific Biosciences of California ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ratchthani Leasing Public Company Limited
BK:THANI
|
0.127x |
|
Hu Lane Associate
TWO:6279
|
0.019x |
|
Sports Gear Co. Ltd
TW:6768
|
-0.047x |
|
SUNSEA Telecommunications Co Ltd
SHE:002313
|
0.074x |
|
Medistim ASA
OL:MEDI
|
0.098x |
|
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
|
0.053x |
|
Wilson Bayly Holmes Ovcon Ltd
JSE:WBO
|
0.150x |
|
Delek Automotive Systems Ltd
TA:DLEA
|
0.164x |
Annual Cash Flow Conversion Efficiency for Pacific Biosciences of California (2008–2025)
The table below shows the annual cash flow conversion efficiency of Pacific Biosciences of California from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see PACB stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.35 Million | $-111.21 Million | -20.791x | -5011.38% |
| 2024-12-31 | $506.59 Million | $-206.06 Million | -0.407x | -7.02% |
| 2023-12-31 | $701.30 Million | $-266.55 Million | -0.380x | +18.72% |
| 2022-12-31 | $562.90 Million | $-263.21 Million | -0.468x | -232.67% |
| 2021-12-31 | $790.99 Million | $-111.18 Million | -0.141x | -341.79% |
| 2020-12-31 | $335.49 Million | $19.50 Million | 0.058x | +104.08% |
| 2019-12-31 | $54.92 Million | $-78.31 Million | -1.426x | -144.85% |
| 2018-12-31 | $114.06 Million | $-66.43 Million | -0.582x | +25.73% |
| 2017-12-31 | $86.10 Million | $-67.52 Million | -0.784x | +2.26% |
| 2016-12-31 | $84.67 Million | $-67.93 Million | -0.802x | -23.20% |
| 2015-12-31 | $73.54 Million | $-47.89 Million | -0.651x | +30.48% |
| 2014-12-31 | $54.95 Million | $-51.47 Million | -0.937x | -117.20% |
| 2013-12-31 | $69.18 Million | $-29.83 Million | -0.431x | +38.60% |
| 2012-12-31 | $109.38 Million | $-76.82 Million | -0.702x | -30.59% |
| 2011-12-31 | $191.46 Million | $-102.97 Million | -0.538x | -23.38% |
| 2010-12-31 | $279.87 Million | $-122.00 Million | -0.436x | -203.17% |
| 2009-12-31 | $-177.12 Million | $-74.84 Million | 0.423x | +3.02% |
| 2008-12-31 | $-93.39 Million | $-38.30 Million | 0.410x | -- |
About Pacific Biosciences of California
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stran… Read more